Iron Dextran

Screening for iron deficiency at a ferritin threshold of under 25µg/L is cost-effective and more accurate for women, generating 24.3 Quality-Adjusted Life Years (QALYs) vs. 23.3 QALYs at 15 µg/L. Treatment with iron dextran is also cost-effective.

101,746 AE reports analyzed, 68,492 (67.3%) female, 32,547 (32.0%) male; average age 69.8 ± 11.5 (female), 71.5 ± 11.2 (male). Report numbers fluctuated since 2004, peaking 2010-2012 and 2018-2019. Most reports from America (62.3% female, 55.4% male), mainly hospitalization (51.3% female, 51.2% male). Multiple sclerosis most reported AE (14.2% female, 6.2% male). Signals detected using ROR and BCPNN algorithms; top signals varied by sex. Sex differences in signal numbers noted in 2nd-level ATC classes. F/M ratio analysis on shared signals showed 33 positive for females, 38 for males, 48 no difference. Specific drugs showed stronger associations with falls in one sex over the other across various ATC classifications.

Fisons anticipates FDA and British health authority inspections of Opticrom and Imferon facilities in Holmes Chapel by March, paving the way for U.S. reintroduction. Tilade inhaler approval expected soon. Chairman and CEO John Kerridge resigned due to health issues, succeeded by Patrick Egan. Fisons profits declined due to U.S. market absence of Opticrom and Imferon.